CO2021006114A2 - Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer - Google Patents

Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer

Info

Publication number
CO2021006114A2
CO2021006114A2 CONC2021/0006114A CO2021006114A CO2021006114A2 CO 2021006114 A2 CO2021006114 A2 CO 2021006114A2 CO 2021006114 A CO2021006114 A CO 2021006114A CO 2021006114 A2 CO2021006114 A2 CO 2021006114A2
Authority
CO
Colombia
Prior art keywords
treatment
cancer
pyrrolo
pyridin
dihydro
Prior art date
Application number
CONC2021/0006114A
Other languages
English (en)
Inventor
Mehran Jalaie
Rebecca Anne Gallego
Sajiv Krishnan Nair
Robert Steven Kania
Omar Khaled Ahmad
Ted William Johnson
Jamison Bryce Tuttle
Michele Ann Mctigue
Dahui Zhou
Bel Matthew L Del
Ru Zhou
Mingying He
Anne-Marie Dechert Schmitt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO2021006114A2 publication Critical patent/CO2021006114A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La presente invención se refiere a compuestos de la Fórmula general (I) y sales de estos aceptables desde el punto de vista farmacéutico, en donde R1, R1a, R2, , R3, R4, y (R5)a son como se definen en la presente, a composiciones farmacéuticas que comprenden dichos compuestos y sales de estos aceptables desde el punto de vista farmacéutico, y a métodos de uso de dichos compuestos, sales de estos aceptables desde el punto de vista farmacéutico y composiciones para el tratamiento del crecimiento anormal de células, que incluye cáncer.
CONC2021/0006114A 2018-11-15 2021-05-11 Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer CO2021006114A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767602P 2018-11-15 2018-11-15
US201962909970P 2019-10-03 2019-10-03
PCT/IB2019/059702 WO2020100027A1 (en) 2018-11-15 2019-11-12 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
CO2021006114A2 true CO2021006114A2 (es) 2021-05-31

Family

ID=68771726

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0006114A CO2021006114A2 (es) 2018-11-15 2021-05-11 Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer

Country Status (36)

Country Link
US (1) US11142525B2 (es)
EP (1) EP3880676B1 (es)
JP (1) JP7118267B2 (es)
KR (1) KR20210090675A (es)
CN (1) CN113316576A (es)
AU (1) AU2019378184B2 (es)
BR (1) BR112021008991A2 (es)
CA (1) CA3061392A1 (es)
CL (1) CL2021001190A1 (es)
CO (1) CO2021006114A2 (es)
CR (1) CR20210251A (es)
CU (1) CU20210035A7 (es)
DK (1) DK3880676T3 (es)
DO (1) DOP2021000088A (es)
EC (1) ECSP21034668A (es)
ES (1) ES2958948T3 (es)
FI (1) FI3880676T3 (es)
GE (1) GEP20227434B (es)
HR (1) HRP20231089T1 (es)
HU (1) HUE063367T2 (es)
IL (1) IL283149A (es)
LT (1) LT3880676T (es)
MD (1) MD3880676T2 (es)
MX (1) MX2021005754A (es)
PE (1) PE20211868A1 (es)
PH (1) PH12021551117A1 (es)
PL (1) PL3880676T3 (es)
PT (1) PT3880676T (es)
RS (1) RS64655B1 (es)
SG (1) SG11202104394XA (es)
SI (1) SI3880676T1 (es)
TW (1) TWI718758B (es)
UA (1) UA127426C2 (es)
UY (1) UY38471A (es)
WO (1) WO2020100027A1 (es)
ZA (1) ZA202103099B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202103839UA (en) 2018-10-31 2021-05-28 Gilead Sciences Inc Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TW202136261A (zh) 2018-10-31 2021-10-01 美商基利科學股份有限公司 經取代之6-氮雜苯并咪唑化合物
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
CN115698004A (zh) * 2020-05-01 2023-02-03 辉瑞公司 作为hpk1抑制剂的氮杂内酰胺化合物
CN112409268A (zh) * 2020-12-03 2021-02-26 西南交通大学 靶向Fam20C抑制剂的制备及其抗三阴性乳腺癌作用
WO2022258044A1 (zh) * 2021-06-11 2022-12-15 杭州中美华东制药有限公司 吡咯并吡啶酮类化合物及其制备方法和用途
TW202321239A (zh) 2021-07-20 2023-06-01 瑞典商阿斯特捷利康公司 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺
WO2023023942A1 (en) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same
WO2023030478A1 (zh) * 2021-09-03 2023-03-09 浙江海正药业股份有限公司 吡啶并内酰胺类衍生物及其制备方法和用途
WO2023057883A1 (en) * 2021-10-05 2023-04-13 Pfizer Inc. Crystalline form of azalactam compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5243049A (en) * 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CN101801958B (zh) * 2007-07-19 2014-01-29 默沙东公司 作为蛋白质激酶抑制剂的杂环酰胺化合物
US10800773B2 (en) 2016-09-12 2020-10-13 Integral Health, Inc. Monocyclic compounds useful as GPR120 modulators
JP7132937B2 (ja) 2017-03-15 2022-09-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｐｋ１の阻害剤としてのアザインドール
TW201908306A (zh) 2017-07-18 2019-03-01 大陸商南京聖和藥業股份有限公司 作為ask抑制劑的雜環化合物及其應用
US20220324835A1 (en) 2018-01-26 2022-10-13 Nurix Therapeutics, Inc. Inhibitors of cbl-b and methods of use thereof

Also Published As

Publication number Publication date
MD3880676T2 (ro) 2023-12-31
UA127426C2 (uk) 2023-08-16
TWI718758B (zh) 2021-02-11
RS64655B1 (sr) 2023-10-31
LT3880676T (lt) 2023-09-25
PT3880676T (pt) 2023-10-04
DOP2021000088A (es) 2021-06-30
AU2019378184B2 (en) 2022-09-15
AU2019378184A1 (en) 2021-05-27
SI3880676T1 (sl) 2023-10-30
PL3880676T3 (pl) 2023-12-11
PE20211868A1 (es) 2021-09-21
PH12021551117A1 (en) 2021-11-22
WO2020100027A1 (en) 2020-05-22
US11142525B2 (en) 2021-10-12
BR112021008991A2 (pt) 2021-08-10
TW202031657A (zh) 2020-09-01
EP3880676A1 (en) 2021-09-22
FI3880676T3 (fi) 2023-09-15
CA3061392A1 (en) 2020-05-15
KR20210090675A (ko) 2021-07-20
SG11202104394XA (en) 2021-05-28
JP7118267B2 (ja) 2022-08-15
DK3880676T3 (da) 2023-09-04
UY38471A (es) 2020-06-30
CU20210035A7 (es) 2021-12-08
ZA202103099B (en) 2023-11-29
ECSP21034668A (es) 2021-06-30
EP3880676B1 (en) 2023-08-02
MX2021005754A (es) 2021-08-11
HUE063367T2 (hu) 2024-01-28
JP2022507231A (ja) 2022-01-18
ES2958948T3 (es) 2024-02-16
CN113316576A (zh) 2021-08-27
CR20210251A (es) 2021-07-14
GEP20227434B (en) 2022-10-25
HRP20231089T1 (hr) 2023-12-22
IL283149A (en) 2021-06-30
CL2021001190A1 (es) 2021-12-24
US20200172539A1 (en) 2020-06-04

Similar Documents

Publication Publication Date Title
CO2021006114A2 (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer
UY38553A (es) Inhibidores de cdk2
NI201900013A (es) Inhibidor de piridopirimidinona cdk2/4/6
UY38196A (es) Inhibidores de cinasa dependientes de ciclina
UY37900A (es) Nuevos derivados de rapamicina
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
UY39193A (es) Compuestos de azalactama como inhibidores de hpk1
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
CO2020004977A2 (es) Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa
DOP2023000281A (es) Inhibidores de mutación de her2
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
ECSP18056196A (es) Derivados de indano
CO2021000782A2 (es) Agentes inhibidores de ask1
CO2021003218A2 (es) Agentes inhibidores de ask1
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
CU20140033A7 (es) Derivados de pirrolopirimidina y purina
DOP2016000326A (es) Compuestos de dihidroisoquinolinona sustituida
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida